Anti-inflamatory dose doxycycline in the treatment of rosacea

Journal of Drugs in Dermatology

Volumn 8, Issue 7, 2009, Pages 664-668

  Del Rosso, James Q ^a  

^a VALLEY HOSPITAL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; METRONIDAZOLE; ANTIINFECTIVE AGENT; ANTIINFLAMMATORY AGENT;

ABDOMINAL PAIN; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ANTIBIOTIC THERAPY; ANTIINFLAMMATORY ACTIVITY; AREA UNDER THE CURVE; ARTICLE; DIARRHEA; DISEASE SEVERITY; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG EFFICACY; DRUG EXPOSURE; DRUG FORMULATION; DRUG RELEASE; DRUG SAFETY; ERYTHEMA; ESOPHAGUS PAIN; HUMAN; INFLAMMATION; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTICENTER STUDY (TOPIC); NAUSEA; PHARMACOKINETICS; PHASE 3 CLINICAL TRIAL (TOPIC); PHASE 4 CLINICAL TRIAL (TOPIC); PHOTOSENSITIVITY; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); ROSACEA; TREATMENT DURATION; VAGINA CANDIDIASIS; VOMITING; CLINICAL TRIAL; DOSE RESPONSE; DRUG COMBINATION; HOSPITALIZATION; PATHOPHYSIOLOGY; UNITED STATES;

ANTI-INFECTIVE AGENTS; ANTI-INFLAMMATORY AGENTS; CLINICAL TRIALS AS TOPIC; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXYCYCLINE; DRUG THERAPY, COMBINATION; HUMANS; METRONIDAZOLE; ROSACEA; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 67651151616     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Pelle MT, Crawford GH, James WD. Rosacea: II. Therapy. J Am Acad Dermatol. 2004;51(4):499-512.
2. Del Rosso JQ. Medical treatment of rosacea with emphasis on topical therapies. Expert Opinion Pharmacother. 2004;5(1):5-13. (Pubitemid 38072714)
3. Leyden JJ, Del Rosso JQ, Webster GF. Clinical considerations in the treatment of acne and other inflammatory skin disorders: A status report. Dermatol Clin. 2009;27(1):1-15.
4. Bamford JT. Rosacea: Current thoughts on origin. Semin Cutan Med Surg. 2001;20(3):199-206. (Pubitemid 32927782)
5. Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327-341. (Pubitemid 39178655)
6. Del Rosso JQ. Update on rosacea pathogenesis and correlation with medical therapeutic agents. Cutis. 2006;78(2):97-100. (Pubitemid 44433118)
7. Wilkin JK. Rosacea: Pathophysiology and treatment. Arch Dermatol. 1994;130(3):359-362. (Pubitemid 24107876)
8. Sapadin AN, Fleischmajer R. Tetracyclines: Nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258-265. (Pubitemid 43144395)
9. Webster G, Del Rosso JQ. Anti-inflammatory activity of tetracyclines. Dermatol Clin. 2007;25(2):133-135. (Pubitemid 46566395)
10. Golub LM, Ramamurthy NS, Mcnamara TF, et al. Tetracyclines inhibit tissue collagenase activity: A new mechanism in the treatment of periodontal disease. J Periodontal Res. 1984;19(6):651-655. (Pubitemid 15168777)
11. Martin RR, Warr GA, Couch RB, Yeager H, Knight V. Effects of tetracyclines on leukotaxis. J Infect Dis. 1974;129(2):110-116.
12. Esterly NB, Furey NL, Flanagan LE. The effect of antimicrobial agents on leukocyte chemotaxis. J Invest Dermatol. 1978;70(1):51-55. (Pubitemid 8262275)
13. Amin AR, Attur MG, Thakker GD, et al. A novel mechanism of action of tetracyclines: Effects of nitric oxide synthetases. Proc Nat Acad Sci USA. 1996;93:14014-14019. (Pubitemid 26424237)
14. Golub LM, Lee HM, Ryan ME, et al. Tetracyclines inhibit connective tissue breakdown by multiple non-antimicrobial mechanisms. Adv Dent Res. 1998;12(2):12-26.
15. Del Rosso JQ, Webster GF, Jackson M, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791-802. (Pubitemid 46561002)
16. Oracea [package insert], Galderma Pharmaceuticals, Fort Worth, Texas, 2006.
17. Preshaw PM, Novak MJ, Mellonig J, et al. Modified-release subantimicrobial dose doxycycline enhances scaling and root planing in subjects with periodontal disease. J Periodontol. 2008;79(3):440-452.
18. Del Rosso JQ. When an antibiotic is not an antibiotic. Skin and Aging. 2004;12:36-42.
19. Theobald K, Bradshaw M, Leyden J. Anti-inflammatory dose doxycycline (40 mg controlled-release) confers maximum anti-inflammatory efficacy in rosacea. SkinMed. 2007;6(5):221-226.
20. Fowler JF. Combined of anti-inflammatory dose doxycycline (40-mg doxycycline, USP monohydrate controlled-release capsules) and metronidazole topical gel 1% in the treatment of rosacea. J Drugs Dermatol. 2007;6(6):641-645.
21. Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100 mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573-576.
22. Layton AM, Cunliffe WJ. Phototoxic eruption s due to doxycycline - A dose-related phenomenon. Clin Exp Dermatol. 1993;18:425-427. (Pubitemid 23285468)
23. Levy RM, Huang EY, Roling D, et al. Effect of antibiotics on the oropharyngeal flora in patients with acne. Arch Dermatol. 2003;139(4):467-471. (Pubitemid 36427611)
24. Margolis DJ, Bowe WP, Hoffstad O, Berlin JA. Antibiotic treatment of acne may be associated with upper respiratory tract infections. Arch Dermatol. 2005;141(9):1132-1136.